Details

Autor(en) / Beteiligte

• Fatemi, H.M.
• Popovic-Todorovic, B.
• Papanikolaou, E.
• Donoso, P.
• Devroey, P.

Titel

An update of luteal phase support in stimulated IVF cycles

Ist Teil von

• Human reproduction update, 2007-11, Vol.13 (6), p.581-590

Ort / Verlag

England: Oxford University Press

Erscheinungsjahr

2007

Link zum Volltext

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Stimulated IVF cycles are associated with luteal phase defect. In order to overcome this, different doses, durations and types of luteal phase support (LPS) have been evaluated. There is still no agreement regarding the optimal supplementation scheme. The aim of this paper is to assess the past and the current clinical practices of luteal supplementation in IVF. The databases of Medline and PubMed were searched to identify relevant publications. LPS with human chorionic gonadotrophin (hCG) [n = 262, odds ratio (OR) 2.72 (95%), confidence interval (CI) 1.56–4.90, P < 0.05] or progesterone (n = 260, OR 1.57 CI 1.13, 2.17, P < 0.05) results in an increased pregnancy rate compared with placebo, however, hCG is associated with increased risk of ovarian hyperstimulation syndrome. Natural micronized progesterone is not efficient if taken orally. The data on oral dydrogesterone are still conflicting. Vaginal and intra muscular progesterone have comparable outcomes. The addition of estradiol (E2) seems to be beneficial in long GnRH agonist protocol (implantation rate 39.6% with E2 compared with no E2; P < 0.05) but not in the short GnRH agonist and GnRH antagonist protocol. Despite the early promising results, it is too early to recommend the use of GnRH agonist in LPS. LPS should cease on the day of positive HCG. Since the cause of luteal phase defect in IVF appears to be related to the supraphysiological levels of steroids, milder stimulation protocols should be advocated in order to eventually overcome the luteal phase defect.